Your browser doesn't support javascript.
loading
Individualized pretest risk estimates to guide treatment decisions in patients with clinical high risk for psychotic disorders.
Sprüngli-Toffel, Elodie; Studerus, Erich; Curtis, Logos; Conchon, Caroline; Alameda, Luis; Bailey, Barbara; Caron, Camille; Haase, Carmina; Gros, Julia; Herbrecht, Evelyn; Huber, Christian G; Riecher-Rössler, Anita; Conus, Philippe; Solida, Alessandra; Armando, Marco; Kapsaridi, Afroditi; Mercapide Ducommun, Mathieu; Klauser, Paul; Jessica Plessen, Kerstin; Urben, Sébastien; Edan, Anne; Nanzer, Nathalie; Liso Navarro, Ana; Schneider, Maude; Genoud, Davina; Michel, Chantal; Kindler, Jochen; Kaess, Michael; Oliver, Dominic; Fusar-Poli, Paolo; Borgwardt, Stefan; Andreou, Christina.
Afiliação
  • Sprüngli-Toffel E; General Psychiatry Service, Lausanne University Hospital (CHUV), University of Lausanne, Lausanne, Switzerland; Department of Psychiatry, University of Geneva, Geneva, Switzerland. Electronic address: elodie.sprungli-toffel@chuv.ch.
  • Studerus E; Institute for Information Systems, University of Applied Sciences and Arts Northwestern Switzerland, Basel, Switzerland.
  • Curtis L; Department of Psychiatry, University of Geneva, Geneva, Switzerland; Department of Adult Psychiatry, Department of Psychiatry, Geneva University Hospital, University of Geneva, Geneva, Switzerland.
  • Conchon C; General Psychiatry Service, Lausanne University Hospital (CHUV), University of Lausanne, Lausanne, Switzerland.
  • Alameda L; General Psychiatry Service, Lausanne University Hospital (CHUV), University of Lausanne, Lausanne, Switzerland; King's College of London, Institute of Psychiatry, Psychology and Neuroscience, London, United Kingdom; Centro Investigacion Biomedica en Red de Salud Mental (CIBERSAM); Instituto de Biome
  • Bailey B; University Psychiatric Clinics (UPK) Basel, University of Basel, Basel, Switzerland.
  • Caron C; University Psychiatric Clinics (UPK) Basel, University of Basel, Basel, Switzerland.
  • Haase C; University Psychiatric Clinics (UPK) Basel, University of Basel, Basel, Switzerland.
  • Gros J; University Psychiatric Clinics (UPK) Basel, University of Basel, Basel, Switzerland.
  • Herbrecht E; University Psychiatric Clinics (UPK) Basel, University of Basel, Basel, Switzerland.
  • Huber CG; University Psychiatric Clinics (UPK) Basel, University of Basel, Basel, Switzerland.
  • Riecher-Rössler A; Medical Faculty, University of Basel, Basel, Switzerland.
  • Conus P; General Psychiatry Service, Lausanne University Hospital (CHUV), University of Lausanne, Lausanne, Switzerland.
  • Solida A; General Psychiatry Service, Lausanne University Hospital (CHUV), University of Lausanne, Lausanne, Switzerland; Center of Psychiatry of Neuchâtel (CNP), Neuchâtel, Switzerland.
  • Armando M; Division of Child and Adolescent Psychiatry, Lausanne University Hospital and the University of Lausanne, Lausanne, Switzerland; Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.
  • Kapsaridi A; Division of Child and Adolescent Psychiatry, Lausanne University Hospital and the University of Lausanne, Lausanne, Switzerland.
  • Mercapide Ducommun M; Division of Child and Adolescent Psychiatry, Lausanne University Hospital and the University of Lausanne, Lausanne, Switzerland.
  • Klauser P; Division of Child and Adolescent Psychiatry, Lausanne University Hospital and the University of Lausanne, Lausanne, Switzerland; Center for psychiatric neuroscience, Lausanne University Hospital and the University of Lausanne, Lausanne, Switzerland.
  • Jessica Plessen K; Division of Child and Adolescent Psychiatry, Lausanne University Hospital and the University of Lausanne, Lausanne, Switzerland; Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.
  • Urben S; Division of Child and Adolescent Psychiatry, Lausanne University Hospital and the University of Lausanne, Lausanne, Switzerland; Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.
  • Edan A; Child and Adolescent Psychiatric Service, Geneva University Hospitals, University of Geneva, Geneva, Switzerland.
  • Nanzer N; Child and Adolescent Psychiatric Service, Geneva University Hospitals, University of Geneva, Geneva, Switzerland.
  • Liso Navarro A; Medico-Pedagogical Office, State of Geneva, Geneva, Switzerland.
  • Schneider M; Faculty of Psychology and Educational Sciences, University of Geneva, Geneva, Switzerland.
  • Genoud D; Division of Child and Adolescent Psychiatry, Lausanne University Hospital and the University of Lausanne, Lausanne, Switzerland.
  • Michel C; University Hospital of Child and Adolescent Psychiatry and Psychotherapy, University of Bern, Bern, Switzerland.
  • Kindler J; University Hospital of Child and Adolescent Psychiatry and Psychotherapy, University of Bern, Bern, Switzerland.
  • Kaess M; University Hospital of Child and Adolescent Psychiatry and Psychotherapy, University of Bern, Bern, Switzerland.
  • Oliver D; Department of Psychiatry, University of Oxford, Oxford, United Kingdom.
  • Fusar-Poli P; King's College of London, Institute of Psychiatry, Psychology and Neuroscience, London, United Kingdom; OASIS service, South London and the Maudsley NHS Foundation Trust, London, United Kingdom; Department of Brain and Behavioural Sciences, University of Pavia, Pavia, Italy; Department of Psychiatry
  • Borgwardt S; Department of Psychiatry and Psychotherapy, Translational Psychiatry Unit, University of Lübeck, Lübeck, Germany.
  • Andreou C; Department of Psychiatry and Psychotherapy, Translational Psychiatry Unit, University of Lübeck, Lübeck, Germany.
Article em En | MEDLINE | ID: mdl-39303874
ABSTRACT

INTRODUCTION:

Clinical High Risk for Psychosis (CHR) states are associated with an increased risk of transition to psychosis. However, the predictive value of CHR screening interviews is dependent on pretest risk enrichment in referred patients. This poses a major obstacle to CHR outreach campaigns since they invariably lead to risk dilution through enhanced awareness. A potential compensatory strategy is to use estimates of individual pretest risk as a 'gatekeeper' for specialized assessment. We aimed to test a risk stratification model previously developed in London, UK (OASIS) and to train a new predictive model for the Swiss population.

METHOD:

The sample was composed of 513 individuals referred for CHR assessment from six Swiss early psychosis detection services. Sociodemographic variables available at referral were used as predictors whereas the outcome variable was transition to psychosis.

RESULTS:

Replication of the risk stratification model developed in OASIS resulted in poor performance (Harrel's c = 0.51). Retraining resulted in moderate discrimination (Harrel's c = 0.67) which significantly differentiated between different risk groups. The lowest risk group had a cumulative transition incidence of 6.4% (CI 0% - 23.1%) over two years.

CONCLUSION:

Failure to replicate the OASIS risk stratification model might reflect differences in the public health care systems and referral structures between Switzerland and London. Retraining resulted in a model with adequate discrimination performance. The developed model in combination with CHR assessment result, might be useful for identifying individuals with high pretest risk, who might benefit most from specialized intervention.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article